RATIONALE: Several recent studies have focused on glutamate modulating agents for symptoms relief in schizophrenia, especially negative symptoms which are resistant to conventional therapies. OBJECTIVES: We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia. METHODS: In this randomized double-blind placebo-controlled parallel-group study, 50 patients with chronic schizophrenia and a score of ≥20 on the negative subscale of positive and negative syndrome scale (PANSS) were enrolled in the active phase of their illness. Participants were equally randomized to receive riluzole (100 mg/day) or placebo in addition to risperidone (up to 6 mg/day) for 8 weeks. Participants were rated by PANSS every 2 weeks. The primary outcome of this study was the difference in the decrease of PANSS negative subscale score from baseline to the study endpoint between the two groups. RESULTS: By the study endpoint, riluzole-treated patients showed significantly greater improvement in the negative symptoms (P < 0.001) as well as the PANSS total and general psychopathology subscale scores (P = 0.001 and P < 0.001; respectively) compared to the placebo group. Treatment group was the only significant predictor of changes in negative symptom in this trial (β = -0.56, P < 0.001). No significant difference was observed between two groups in the frequency of side effects. CONCLUSION: These preliminary findings suggest that riluzole may be a safe and effective medication for the treatment of negative symptoms in patients with chronic schizophrenia. Further research and replication of study findings is warranted. Clinical trial registry name and registration number: Iranian registry of clinical trials www.irct.ir , IRCT201107281556N26
RCT Entities:
RATIONALE: Several recent studies have focused on glutamate modulating agents for symptoms relief in schizophrenia, especially negative symptoms which are resistant to conventional therapies. OBJECTIVES: We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia. METHODS: In this randomized double-blind placebo-controlled parallel-group study, 50 patients with chronic schizophrenia and a score of ≥20 on the negative subscale of positive and negative syndrome scale (PANSS) were enrolled in the active phase of their illness. Participants were equally randomized to receive riluzole (100 mg/day) or placebo in addition to risperidone (up to 6 mg/day) for 8 weeks. Participants were rated by PANSS every 2 weeks. The primary outcome of this study was the difference in the decrease of PANSS negative subscale score from baseline to the study endpoint between the two groups. RESULTS: By the study endpoint, riluzole-treated patients showed significantly greater improvement in the negative symptoms (P < 0.001) as well as the PANSS total and general psychopathology subscale scores (P = 0.001 and P < 0.001; respectively) compared to the placebo group. Treatment group was the only significant predictor of changes in negative symptom in this trial (β = -0.56, P < 0.001). No significant difference was observed between two groups in the frequency of side effects. CONCLUSION: These preliminary findings suggest that riluzole may be a safe and effective medication for the treatment of negative symptoms in patients with chronic schizophrenia. Further research and replication of study findings is warranted. Clinical trial registry name and registration number: Iranian registry of clinical trials www.irct.ir , IRCT201107281556N26
Authors: John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman Journal: Psychopharmacology (Berl) Date: 2003-09-02 Impact factor: 4.530
Authors: Vladimir Coric; Sarper Taskiran; Christopher Pittenger; Suzanne Wasylink; Daniel H Mathalon; Gerald Valentine; John Saksa; Yu-Te Wu; Ralitza Gueorguieva; Gerard Sanacora; Robert T Malison; John H Krystal Journal: Biol Psychiatry Date: 2005-09-01 Impact factor: 13.382
Authors: Sanjay J Mathew; Jonathan M Amiel; Jeremy D Coplan; Heidi A Fitterling; Harold A Sackeim; Jack M Gorman Journal: Am J Psychiatry Date: 2005-12 Impact factor: 18.112
Authors: Russell L McLaughlin; Dick Schijven; Wouter van Rheenen; Kristel R van Eijk; Margaret O'Brien; René S Kahn; Roel A Ophoff; An Goris; Daniel G Bradley; Ammar Al-Chalabi; Leonard H van den Berg; Jurjen J Luykx; Orla Hardiman; Jan H Veldink Journal: Nat Commun Date: 2017-03-21 Impact factor: 14.919
Authors: Toby Pillinger; Maria Rogdaki; Robert A McCutcheon; Pamela Hathway; Alice Egerton; Oliver D Howes Journal: Psychopharmacology (Berl) Date: 2019-02-28 Impact factor: 4.530